Medical Developments International Limited · ASX:MVP
Medical Developments International — Shareholder Meeting (October 2023)
25 slides from Medical Developments International's shareholder meeting presentation, Oct 27, 2023
Slide 1: FY23 Annual General Meeting
For personal use only ASX:MVP FY23 ANNUAL GENERAL MEETING 27 OCTOBER 2023 1
Slide 2: Important information
Important information For personal use only This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions
Slide 3: Important information (cont)
Important information (cont) For personal use only There can be no assurance that any existing or future regulatory filings will satisfy any health authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by
Slide 4: Gordon Naylor, Company Chair
For personal use only Gordon Naylor Company Chair 4
Slide 5: Your Board
Your Board For personal use only Gordon Naylor Dr. Russell Richard Betts Christine Leon Hoare Mary Sontrop Company Chair Basser Independent Non-executive Emmanuel- Independent Non-executive Independent Non-executive Director Director Director Independent Non-executive Donnelly Director Independent N
Slide 6: How to ask a question
How to ask a question For personal use only • To ask a written question select the Q & A icon • Select the topic your question relates to from the drop-down list • Type your question in the text box and press the send button • To ask a verbal question follow the instructions below the broadcast wind
Slide 7: How to vote
How to vote For personal use only • When the poll is open, select the vote icon at the top of the screen • To vote, select either For, Against or Abstain • You will see a vote confirmation • To change or cancel your vote “click here to change your vote” at any time until the poll is closed 7
Slide 8: Solid progress in FY23
For personal use only Solid progress in FY23 8
Slide 9: CEO Brent MacGregor
For personal use only 9 CEO Brent MacGregor
Slide 10: For personal use only
For personal use only 10 1.Excludes Contract termination revenue of $18.9 million (refer to the Full Year Consolidated Financial Report) 2.Refer to page 22 of the FY23 Full Year Results Investor Presentation for a summary of Underlying Adjustments.
Slide 11: FY24 priorities
FY24 priorities For personal use only Deliver improved earnings and cashflow and advance US market entry 1. Improve margins through pricing and operational efficiency 2. Increase penetration of Penthrox in Australian hospital emergency departments (EDs) 3. Review go‐to‐market model for Europe 4. Pro
Slide 12: Formal Business
For personal use only 12 Formal Business
Slide 13: Adoption of the Remuneration Report
Resolution 1 For personal use only “That the Remuneration Report for the year ended 30 June 2023 as set out in the Company’s Annual Report for the year ended 30 June 2023 be adopted.” 13
Slide 14: 1: Proxy results
Resolution 1: Proxy results For personal use only For Against Open Abstain No. Of Shares 24,197,786 741,408 364,234 68,400 % of Total 95.63 2.93 1.44 N/A Proxies 14
Slide 15: Re-election of Christine Emmanuel-Donnelly
Resolution 2 For personal use only “That pursuant to the Company’s Constitution and for all other purposes, the members of the Company approve the re-election of Ms Christine Emmanuel-Donnelly as a Non-Executive Director of the Company, who pursuant to clause 12.4 of the Company’s Constitution is re
Slide 16: 2: Proxy results
Resolution 2: Proxy results For personal use only For Against Open Abstain No. Of Shares 25,256,770 425,280 359,187 79,474 % of Total 96.98 1.64 1.38 N/A Proxies 16
Slide 17: Re-election of Mary Sontrop
Resolution 3 For personal use only “That pursuant to the Company’s Constitution and for all other purposes, the members of the Company approve the re-election of Ms Mary Sontrop as a Non- Executive Director of the Company, who pursuant to clause 12.4 of the Company’s Constitution is retiring by rota
Slide 18: 3: Proxy results
Resolution 3: Proxy results For personal use only For Against Open Abstain No. Of Shares 25,259,637 421,993 359,607 79,474 % of Total 97.00 1.62 1.38 N/A Proxies 18
Slide 19: Election of Dr Russell Basser
Resolution 4 For personal use only “ That pursuant to the Company’s Constitution and for all other purposes, the members of the Company approve the election of Dr Russell Basser as a Non- Executive Director of the Company, who pursuant to clause 12.6.2 of the Company’s Constitution is retiring as a
Slide 20: 4: Proxy results
Resolution 4: Proxy results For personal use only For Against Open Abstain No. Of Shares 25,310,845 360,209 360,867 88,790 % of Total 97.23 1.39 1.38 N/A Proxies 20
Slide 21: Approval of Employee Incentive Scheme
Resolution 5 For personal use only “That the shareholders approve the Company’s Employee Incentive Scheme for the purposes of ASX Listing Rule 7.2 Exception 13(b), sections 200B, 200E and 259B(2) of the Corporations Act 2001, and for all other purposes, as laid before the meeting, a copy of which is
Slide 22: 5: Proxy results
Resolution 5: Proxy results For personal use only For Against Open Abstain No. Of Shares 24,072,387 750,606 356,187 120,140 % of Total 95.60 2.98 1.42 N/A Proxies 22
Slide 23: Cancellation of CEO Options
Resolution 6 For personal use only “That pursuant to and in accordance with ASX Listing Rule 6.23.2 and 6.23.4 and for all other purposes, Shareholders approve the cancellation of 1,968,704 Options issued to Brent MacGregor on 1 November 2020 (CEO Options) and in their place procure a transfer to Br
Slide 24: 5: Proxy results
Resolution 5: Proxy results For personal use only For Against Open Abstain No. Of Shares 25,234,793 488,240 360,187 37,491 % of Total 96.75 1.87 1.38 N/A Proxies 24
Slide 25: Closure
For personal use only 25 Closure
Medical Developments International — Shareholder Meeting (October 2023) on 6ix